Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments

(2020) Navid Sobhani et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.

(2020) Fabrice Andre et al.   JOURNAL OF CLINICAL ONCOLOGY

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer

(2020) Seth A. Wander et al.   Cancer Discovery

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer

(2020) Pingping Mao et al.   CLINICAL CANCER RESEARCH

Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition

(2020) Anne Fassl et al.   Science Advances

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance

(2019) Liam Cornell et al.   Cell Reports

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

(2019) Luigi Formisano et al.   Nature Communications

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer

(2019) Nicholas C. Turner et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors.

(2019) Pedram Razavi et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial.

(2019) Ben O'Leary et al.   JOURNAL OF CLINICAL ONCOLOGY

Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein’s C-Terminal Helix

(2019) Benjamin R. Topacio et al.   MOLECULAR CELL

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

(2019) Sobhani et al.   Cells

PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer

(2019) Carlotta Costa et al.   Cancer Discovery

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

(2018) Dennis J. Slamon et al.   JOURNAL OF CLINICAL ONCOLOGY

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer

(2018) Navid Sobhani et al.   Cells

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Fibroblast growth factor receptor 5 (FGFR5) is a co-receptor for FGFR1 that is up-regulated in beta-cells by cytokine-induced inflammation

(2018) Romario Regeenes et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial

(2018) Ben O'Leary et al.   Cancer Discovery

Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer

(2018) Eric Haines et al.   Oncotarget

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

(2018) Zhiqiang Li et al.   CANCER CELL

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

Targeting CDK4/6 in patients with cancer

(2016) Erika Hamilton et al.   CANCER TREATMENT REVIEWS

Genetic insights into the mechanisms of Fgf signaling

(2016) J. Richard Brewer et al.   GENES & DEVELOPMENT

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation

(2016) K. N. Nelson et al.   MOLECULAR CANCER RESEARCH

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

(2016) C Yang et al.   ONCOGENE

Mechanism of FGF receptor dimerization and activation

(2016) Sarvenaz Sarabipour et al.   Nature Communications

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

(2015) T. Helsten et al.   CLINICAL CANCER RESEARCH

Fgfr1 regulates development through the combinatorial use of signaling proteins

(2015) J. Richard Brewer et al.   GENES & DEVELOPMENT

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Germline variant FGFR4  p.G388R exposes a membrane-proximal STAT3 binding site

(2015) Vijay K. Ulaganathan et al.   NATURE

Clinical Significance of Fibroblast Growth Factor (FGF) Expression in Colorectal Cancer

(2014) Norie Jibiki et al.   INTERNATIONAL SURGERY

The landscape of kinase fusions in cancer

(2014) Nicolas Stransky et al.   Nature Communications

FGFR signalling in women's cancers

(2013) Abbie E. Fearon et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours

(2013) Brittany C Parker et al.   JOURNAL OF PATHOLOGY

FGF Receptors: Cancer Biology and Therapeutics

(2013) Masaru Katoh et al.   MEDICINAL RESEARCH REVIEWS

FGFR2 Promotes Breast Tumorigenicity through Maintenance of Breast Tumor-Initiating Cells

(2013) Sungeun Kim et al.   PLoS One

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

(2012) Jeffry L. Dean et al.   CELL CYCLE

FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

(2012) V. Guagnano et al.   Cancer Discovery

Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition

(2011) Elizabeth Allen et al.   CLINICAL CANCER RESEARCH

FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

(2010) N. Turner et al.   CANCER RESEARCH

Signal Transducers and Activators of Transcription-3 Binding to the Fibroblast Growth Factor Receptor Is Activated by Receptor Amplification

(2010) A. A. Dudka et al.   CANCER RESEARCH

Grb14 inhibits FGF receptor signaling through the regulation of PLCγ recruitment and activation

(2010) Edith Browaeys-Poly et al.   FEBS LETTERS

Regulation of the expression balance of angiopoietin-1 and angiopoietin-2 by Shh and FGF-2

(2010) Takaaki Fujii et al.   IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

(2010) J L Dean et al.   ONCOGENE

Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer

(2010) Arshad A. Pandith et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

The Role of Fibroblast Growth Factors in Tumor Growth

(2009) M. Korc et al.   CURRENT CANCER DRUG TARGETS

Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models

(2009) James G. Taylor VI et al.   JOURNAL OF CLINICAL INVESTIGATION

The Precise Sequence of FGF Receptor Autophosphorylation Is Kinetically Driven and Is Disrupted by Oncogenic Mutations

(2009) E. D. Lew et al.   Science Signaling

Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer

(2008) Simon N Stacey et al.   NATURE GENETICS

Drug-sensitive FGFR2 mutations in endometrial carcinoma

(2008) A. Dutt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer

(2008) Kerstin B Meyer et al.   PLOS BIOLOGY

Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting

(2008) Kristian Pietras et al.   PLOS MEDICINE